The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The aim of this application is to find new therapeutic strategies for genetic epilepsy. "Disease in a dish" models as well as whole animal models will be generated that contain patient gene mutations and the underlying disease processes will be characterised. Using these models a range of existing and new drugs will be tested to select those that most completely reverse these disease processes. These results will feed into clinical trials in patients with appropriate genetic profiles.
Microenvironmental Impact In The Treatment Of Acute Lymphoblastic Leukemia
Funder
National Health and Medical Research Council
Funding Amount
$621,458.00
Summary
Acute lymphoblastic leukemia remains one of the leading causes of death in children and outcomes for adults with this disease remain poor. This project examines how manipulation of the environment where leukemia arises can be used to therpaeutic advancage. Acute lymphoblastic leukemia cells are highly dependent on the support provided by bone marrow cells but the mechanisms are not well understood. Disrupting signals from the bone marrow cells has potential as a therapeutic strategy.
An inability to control human fertility is an issue of global significance. Frequently both unwanted pregnancies and infertility result from the same origin, a lack of understanding of how germ cells are produced. Within this fellowship I will define key processes involved in the manifestation of male fertility. Further I will extend these insights into both the fertility clinic but also into human health more broadly.
Cancers arise as a result of the impairment of critical cellular processes following the mutation of important regulatory genes. I am a molecular biologist and I study how the proteins of the Bcl-2 family regulate apoptosis, a process of cell death essential to maintain homeostasis in multicellular organisms, with the aim of designing drugs to kill cancer cells selectively. I am also interested in discovering new genes involved in the development of cancer using new genomics technology.
Too little or too much of the essential element iron is the cause of some of the most common disorders affecting humans. These include iron overload, anaemia, and anaemia of chronic disease. This project examines the genes and the roles they play in regulating iron levels in the body, and the consequences to the individuals when they are mutated. Ultimately I intend to develop therapeutics and diagnostics which will help early diagnosis and effective treatment of these disorders.
I am a cell /whole body integrative biologist determining the cellular and molecular mechanisms that lead to insulin resistance in insulin sensitive tissues such as skeletal muscle, liver and adipose tissue. My work primarily focuses on targeting inflammatory signalling cascades that lead to impaired insulin action, and pathways that enhance energy utilization.
Biosensor Imaging In Preclinical Pancreatic Cancer Targeting: Taking Cancer Targeting To New Dimensions.
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Using cutting-edge imaging technology and 3D models that mimic cancer, we can map areas of poor drug response within distinct 'stages' or regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug response in order to improve the encouraging anti-cancer profile of new or current drugs in pancreatic cancer.
Identifying And Developing Novel Therapeutic Approaches For Heart Disease
Funder
National Health and Medical Research Council
Funding Amount
$638,517.00
Summary
Increasing rates of obesity, diabetes, and an ageing population increase the risk of heart disease & complications including heart failure (HF), atrial fibrillation (AF), and diabetic heart disease. There is a clinical need for i) improved therapies for patients with HF, AF, and diabetic heart, and ii) biomarkers which more effectively recognise people at risk of heart disease, to prevent clinical events. My research program is designed to develop novel therapies and identify new biomarkers.
Disorderly Conduct And Disturbing The Peace: How Loss Of Cell Polarity And Tissue Architecture Drives Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$638,517.00
Summary
Disorganisation of cells within tumours is a defining feature of aggressive cancers. Using mouse models and 3D organ cultures we have now shown that disruption of a family of organising genes found in every cell confuses the arrangement, orientation and connection of cells within an organ thus causing tumours. Here we will provide a new understanding of how the disorganisation of cells in human tissue leads to cancer and develop new cancer therapeutic approaches to keep tissues well-organised.
Targeting The Interface Between Tumours And Their Microenvironment For The Treatment Of Gastrointestinal Cancers
Funder
National Health and Medical Research Council
Funding Amount
$785,045.00
Summary
This fellowship explores the synergistic interactions between intestinal cancer cells and the tumour microenvironment and which promote survival, expansion, migration and invasion as well as facilitating the development of resistance to anti-cancer therapy. Aided by the clinical expertise of my collaborators, my efforts are likely to yield translational outcomes, including the development of therapeutic IL-11 antagonists, and of a serum protein signature indicative of early stage gastric cancer.